DNA repair in lung cancer: potential not yet reached.
作者信息
Mamdani Hirva, Jalal Shadia I
机构信息
Division of Hematology/Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
Indiana University Melvin & Bren Simon Cancer Center, 980 W Walnut Street, Indianapolis, IN 46202, IN, USA.
出版信息
Lung Cancer Manag. 2016 Apr;5(1):5-8. doi: 10.2217/lmt-2016-0004. Epub 2016 Apr 6.
Abstract
摘要
相似文献
1
DNA repair in lung cancer: potential not yet reached.肺癌中的DNA修复：潜力尚未实现。
Lung Cancer Manag. 2016 Apr;5(1):5-8. doi: 10.2217/lmt-2016-0004. Epub 2016 Apr 6.
2
Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer.应用新一代测序技术重新定义三阴性乳腺癌的 BRCA 状态。
Cancer Sci. 2020 Apr;111(4):1375-1384. doi: 10.1111/cas.14313. Epub 2020 Feb 19.
3
NDRG1 disruption alleviates cisplatin/sodium glycididazole-induced DNA damage response and apoptosis in ERCC1-defective lung cancer cells.NDRG1 缺失可减轻 ERCC1 缺陷型肺癌细胞中顺铂/甘氨双唑钠诱导的 DNA 损伤反应和细胞凋亡。
Int J Biochem Cell Biol. 2018 Jul;100:54-60. doi: 10.1016/j.biocel.2018.05.003. Epub 2018 May 26.
4
New design of nucleotide excision repair (NER) inhibitors for combination cancer therapy.用于联合癌症治疗的核苷酸切除修复（NER）抑制剂的新设计。
J Mol Graph Model. 2016 Apr;65:71-82. doi: 10.1016/j.jmgm.2016.02.010. Epub 2016 Feb 26.
5
ERCC1-XPF deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancers.ERCC1-XPF 缺陷是奥拉帕利诱导上皮性卵巢癌合成致死和铂类敏感性的预测因子。
Gynecol Oncol. 2019 May;153(2):416-424. doi: 10.1016/j.ygyno.2019.02.014. Epub 2019 Feb 21.
6
Pharmacogenetics of platinum-based chemotherapy in non-small cell lung cancer: predictive validity of polymorphisms of ERCC1.非小细胞肺癌中铂类化疗的药物遗传学：ERCC1基因多态性的预测效度
Expert Opin Drug Metab Toxicol. 2018 Jan;14(1):17-24. doi: 10.1080/17425255.2018.1416095. Epub 2017 Dec 18.
7
Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer.核苷酸切除修复通路中着色性干皮病互补组 C 单核苷酸多态性与晚期卵巢癌无进展生存期延长相关。
Cancer. 2012 Feb 1;118(3):689-97. doi: 10.1002/cncr.26329. Epub 2011 Jul 12.
8
Excision repair cross complementing-group 1: gene expression and platinum resistance.切除修复交叉互补基因1：基因表达与铂耐药性
Int J Mol Med. 2004 Dec;14(6):959-70.
9
Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy.铂-DNA加合物、核苷酸切除修复与铂类抗癌化疗
Cancer Treat Rev. 1998 Oct;24(5):331-44. doi: 10.1016/s0305-7372(98)90056-1.
10
PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs.PARP1 对铂类加合物的 DNA 修复的影响：临床前和临床研究结果。
Lung Cancer. 2013 May;80(2):216-22. doi: 10.1016/j.lungcan.2013.01.014. Epub 2013 Feb 12.
引用本文的文献
1
Unravelling the Triad of Lung Cancer, Drug Resistance, and Metabolic Pathways.解析肺癌、耐药性和代谢途径的三联征
Diseases. 2024 May 6;12(5):93. doi: 10.3390/diseases12050093.
2
USNAP: fast unique dense region detection and its application to lung cancer.USNAP：快速唯一密集区域检测及其在肺癌中的应用。
Bioinformatics. 2023 Aug 1;39(8). doi: 10.1093/bioinformatics/btad477.
3
Proteomic Analysis of Lung Cancer Types-A Pilot Study.肺癌类型的蛋白质组学分析——一项初步研究
Cancers (Basel). 2022 May 26;14(11):2629. doi: 10.3390/cancers14112629.
4
A non-genetic, cell cycle-dependent mechanism of platinum resistance in lung adenocarcinoma.肺腺癌铂类耐药的一种非遗传、细胞周期依赖性机制。
Elife. 2021 May 13;10:e65234. doi: 10.7554/eLife.65234.
5
Foreword: message from the Editor.前言：编辑寄语
Lung Cancer Manag. 2016 Dec;5(4):155-157. doi: 10.2217/lmt-2017-0002. Epub 2017 Jun 5.
本文引用的文献
1
Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer.在转移性三阴性乳腺癌患者中，尼拉帕尼联合吉西他滨和卡铂与吉西他滨和卡铂的 III 期研究。
J Clin Oncol. 2014 Dec 1;32(34):3840-7. doi: 10.1200/JCO.2014.55.2984. Epub 2014 Oct 27.
2
ERCC1 isoform expression and DNA repair in non-small-cell lung cancer.非小细胞肺癌中 ERCC1 异构体表达与 DNA 修复。
N Engl J Med. 2013 Mar 21;368(12):1101-10. doi: 10.1056/NEJMoa1214271.
3
Chemotherapy induced DNA damage response: convergence of drugs and pathways.化疗诱导的 DNA 损伤反应：药物与通路的汇聚
Cancer Biol Ther. 2013 May;14(5):379-89. doi: 10.4161/cbt.23761. Epub 2013 Feb 4.
4
Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.蛋白质组学分析鉴定出小细胞肺癌中失调的通路和新的治疗靶点，包括 PARP1。
Cancer Discov. 2012 Sep;2(9):798-811. doi: 10.1158/2159-8290.CD-12-0112. Epub 2012 Sep 6.
5
Lung cancer and DNA repair genes: multilevel association analysis from the International Lung Cancer Consortium.肺癌与 DNA 修复基因：国际肺癌研究协作组的多层次关联分析。
Carcinogenesis. 2012 May;33(5):1059-64. doi: 10.1093/carcin/bgs116. Epub 2012 Mar 1.
6
Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells.XPF-ERCC1 的下调增强了癌细胞中顺铂的疗效。
DNA Repair (Amst). 2010 Jul 1;9(7):745-53. doi: 10.1016/j.dnarep.2010.03.010. Epub 2010 Apr 24.
7
Functional evidence for Eme1 as a marker of cisplatin resistance.Eme1作为顺铂耐药标志物的功能证据。
Int J Cancer. 2009 Jun 15;124(12):2997-3001. doi: 10.1002/ijc.24268.
8
DNA damage and repair capacity in patients with lung cancer: prediction of multiple primary tumors.肺癌患者的DNA损伤与修复能力：多原发性肿瘤的预测
J Clin Oncol. 2008 Jul 20;26(21):3560-6. doi: 10.1200/JCO.2007.13.2654.
9
DNA repair capacity and lung cancer risk in never smokers.从不吸烟者的DNA修复能力与肺癌风险
Cancer Epidemiol Biomarkers Prev. 2008 Jun;17(6):1322-8. doi: 10.1158/1055-9965.EPI-07-2591.
10
DNA repair of oxidative DNA damage in human carcinogenesis: potential application for cancer risk assessment and prevention.人类致癌过程中氧化性DNA损伤的DNA修复：在癌症风险评估与预防中的潜在应用
Cancer Lett. 2008 Jul 18;266(1):60-72. doi: 10.1016/j.canlet.2008.02.032. Epub 2008 Apr 18.
Zotero 插件